You have full text access to this Open Access content

Immunity, Inflammation and Disease

Each article is made available under the terms of the Creative Commons Attribution License

Cover image for Vol. 5 Issue 2

Editor-in-Chief Dr. Marc Veldhoen, Institute for Molecular Medicine, University of Lisbon, Portugal

Online ISSN: 2050-4527

Author Guidelines


1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details


Thank you for your interest in Immunity, Inflammation and Disease. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at

The submission system will prompt you to use an ORCID iD (a unique author identifier) to help distinguish your work from that of other researchers. Click here to find out more.

Click here for more details on how to use ScholarOne

For help with submissions, please contact:

We look forward to your submission.


Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of cutting-edge research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal welcomes original work that enhances the understanding of immunology in areas including:

• cellular and molecular immunology
• clinical immunology
• allergy
• immunochemistry
• immunogenetics
• immune signalling
• immune development
• imaging
• mathematical modelling
• autoimmunity
• transplantation immunology
• cancer immunology

Original research articles, methods papers, editorials and commentaries are published. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper. Immunity, Inflammation and Disease considers for publication both papers submitted directly to the journal and those referred from a select group of prestigious journals published by Wiley.


Immunity, Inflammation and Disease publishes a number of different article types including:

• Original Articles
Reports of new research findings or conceptual analyses that make a significant contribution to knowledge.

• Reviews
Critical reviews of the literature, including systematic reviews and meta-analyses.

• Editorials

• Methods Papers

• Commentaries


Parts of the Manuscript
Manuscripts should be submitted as a Word, RTF, or PDF file for peer-review submission and must be written in English. While individual files for each figure and table are preferred, a single all-inclusive file is permitted for peer-review submission. If accepted, you may be asked to provide production-ready files.

Text File
The text file should be presented in the following order:

Title Page:
(i) Title
(ii) a short running title of less than 50 characters
(iii) the full names of the authors
(iv) the author's institutional affiliations at which the work was carried out, with a footnote for author’s present address if different to where the work was carried out
(v) Name, address, telephone number and email address of corresponding author (corresponding/contact author must match from the main manuscript and on the system)
(vi) Acknowledgments.

Main File:
(vii) structured abstract and keywords
(viii) main text;
(ix) references;
(x) ethical statement
(xi) Tables (each table complete with title and footnotes)
(xii) Figure legends
(xiii)Appendices (if relevant).

The title should be short and informative, containing major keywords related to the content. The title should not contain abbreviations (see Wiley's best practice SEO tips).

For details on eligibility for author listing, please refer to the journal’s Authorship policy outlined in the Editorial Policies and Ethical Considerations section.

Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. See ‘Conflict of Interest’ section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Please provide a structured abstract containing: introduction, methods, results, conclusions.

Please provide 4-6 keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should be superscript numbers. Journal titles are abbreviated; abbreviations may be found in the following: MEDLINE , Index Medicus, or CalTech Library.

Submissions are not required to reflect the precise reference formatting of the journal (use of italics, bold etc.), however it is important that all key elements of each reference are included. Please see below for examples of reference content requirements.

For more information, please see theVancouver Reference style Guide.

Sample references follow:

Journal article
1. Wood WG, Eckert GP, Igbavboa U, Muller WE. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 2010; 1199:69-76.

2. Hoppert, M. Microscopic techniques in biotechnology. Weinheim: Wiley-VCH; 2003.

Electronic Material
3. [homepage on the internet]. New York: Association of Cancer Online Resources, Inc.; c2000–01 [Cited 2015 May 11]. Available from:

Tables should be self-contained and complement, but not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: a, b, c, ..., etc. in superscript, should be used (in that order) and * Asterisks used to indicate significant figures (probability).

Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Preparing Figures
Although we encourage authors to send us the highest-quality figures possible, for peer-review purposes we are happy to accept a wide variety of formats, sizes, and resolutions.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Colour figures
Figures submitted in colour may be reproduced in colour online free of charge.

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Supporting Information
Supporting information is information that is not essential to the article but that provides greater depth and background. It is hosted online, and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information. Note, if data, scripts or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points
The following links provide general advice on formatting and style.
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at for more information about SI units.

• Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).

• Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

• Nomenclature: CD nomenclature is to be used for all cell differentiation antigens, with or without alternative names which give information about the molecules function. Complement receptors should be named CR1 etc., followed by the correct CD terminology in parentheses: CR1 (CD35); CR2 (CD21); CR3 (CDllb, CD18); CR4 (CDllc, CD18).

• Metric System: The metric system should be used for all measurements, weights, etc. Temperatures should be expressed in degrees Celsius (centigrade).

• Flow Cytometry: Flow cytometry experiments should be MIFlowCyt (Minimum Information about a flow cytometry experiment) compliant. See (in particular the documents and, or for further information.

Wiley Author Resources
Manuscript Preparation Tips
Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation and Formatting Support
Wiley Editing Services can greatly improve the chances of your manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting and figure preparation, Wiley Editing Services ensures that your manuscript is ready for submission.


Editorial Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editors-in-Chief determine that the paper meets the appropriate quality and relevance requirements. Wiley's policy on confidentiality of the review process is available here.

Data storage and documentation
Immunity, Inflammation and Disease encourages data sharing wherever possible, unless this is prevented by ethical, privacy or confidentiality matters. Authors publishing in the journal are therefore encouraged to make their data, scripts and other artefacts used to generate the analyses presented in the paper available via a publicly available data repository, however this is not mandatory. If the study includes original data, at least one author must confirm that he or she had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

MEDLINE evaluates a journal's ethical policy by checking that journals ask submitting authors to provide three things: a declaration of conflict of interest (CoI), confirmation that informed consent was sought from test subjects, and that animal rights were taken into consideration. The reviewer will then check three things during the review:

1. Policy Exists: is there evidence in the author guidelines that the journal requires that the appropriate ethical requirements are followed.
2. Policy is Adequate: is the policy appropriate for the journal, e.g. a review journal does not need to have a statement on human/animal rights or informed consent.
3. Policy Consistently Followed: is there evidence in all the published articles that authors have declared their conflicts of interest, and that appropriate procedures were followed when the research was conducted. This will be checked in the final published articles.
We recommend that all articles include a statement regarding COI, regardless of whether or not a COI exists – for example “The authors have stated explicitly that there are no conflicts of interest in connection with this article.”

There should be robust journal workflows in place to ensure all three criteria are met. Examples of failures would be: a journal that requires authors to declare that institutional review board (IRB) approval was sought for their research, but this is not communicated to the readers of the final article; journals that do require declarations of informed consent, but don't say so in the author guidelines; or journals that only publish statements when conflicts-of-interest were declared, and assume that all readers know omission means that there aren't any conflicts.

Human Studies and Subjects
For manuscripts reporting medical studies involving human participants, we require a statement identifying the ethics committee that approved the study, and that the study conforms to recognized standards, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.
Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher, however in signing the author license to publish authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, and the name of the body giving approval, must be included in the Methods section of the manuscript. We encourage authors to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines and regulations for the care and use of laboratory animals:
• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trial Registration
We require that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for this.

Research Reporting Guidelines
Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. We expect authors to adhere to the following:
• Authors of Clinical Trials should adhere to the CONSORTreporting guidelines appropriate to their trial design.
•For reports of epidemiological studies, authors should consult the STROBE initiative.

Dual Use Research
Immunity, Inflammation and Disease expects that all authors will conform to the National Science Advisory Board for Biosecurity (NSABB) guidelines for Dual Use Life Sciences Research. For further information, and a description of ‘dual use research of concern’, please refer to the June 2007 NSABB report. If any of the reported studies may fall in any of these categories, the Editor-in-Chief must be informed at the time of manuscript submission.

Species Names
Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, the scientific name should be used only.

Genetic Nomenclature
Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see, where examples of acceptable nomenclature are provided

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:
• DNA Data Bank of Japan (DDBJ)
• EMBL Nucleotide Archive:
• GenBank

Proteins sequence data Protein sequences, which have been determined by direct sequencing of the protein, must be submitted to SWISS-PROT at the EMBL Outstation –The European Bioinformatics Institute. Results from characterization experiments should also be submitted to SWISS-PROT at the EBI. This can include such information as function, subcellular location, subunit etc.

Database contact/submission emails:
• For sequence submissions:
• For characterization information:

Microarray datasets should be presented in compliance with current practices, for example MGeD Society, and deposited in an accredited database such as Array express or GEO. The corresponding reference to the database entry should be included in the text.

Distribution of Reagents, Strains and Materials
Publication is subject to the understanding that authors will distribute freely any strains, clones or antibodies described therein for use in academic research. Authors might wish to make their plasmid constructs available free of charge through Addgene.

The policy stems from the long-standing scientific principle that authenticity requires reproducibility. Publication in Immunity, Inflammation and Disease constitutes a de facto acceptance of this policy. Included are reagents that can be easily provided; specifically, nucleic acid sequences, cDNA and genomic clones, cell lines, strains and monoclonal antibody clones. Small amounts (sufficient for the replication of any in vitro work reported) of novel protein reagents are also considered easily transferable.

Although the Editors appreciate that many of the reagents mentioned in Immunity, Inflammation and Disease are proprietary or unique, neither condition is considered adequate grounds for deviation from this policy. Suitable material transfer agreements can be drawn up between the provider and requester, but if a reasonable request is turned down and submitted to the Editor-in-Chief, the corresponding author will be held accountable.

Conflict of Interest
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature:

The list of authors should accurately illustrate who contributed to the work and how. Please consult the ICMJE guidelines on authorship for further details.
All those listed as authors should qualify for authorship according to the following criteria:
1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional authorship options
Joint first or senior authorship: In the case of joint first authorship a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

As part of our commitment to supporting authors at every step of the publishing process, Immunity, Inflammation and Disease requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information.

Publication Ethics
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at


Immunity, Inflammation and Disease is an Open Access journal: authors of accepted papers pay an Article Publication Charge and their papers are published under a Creative Commons license. With Creative Commons licenses, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and identify as the original publisher.

Open Access fees: Information on the Article Publication Charge for publishing in the journal is available here.

If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to login to Author Services, where via the Wiley Author Licensing Service (WALS), they will be able to complete the license agreement on behalf of all authors on the paper.

To find out which Created Commons Licenses are available for the journal, click here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate a particular type of CC license be used; to check this, please click here.


Accepted article received in production
When your accepted article is received by Wiley’s production team, you (corresponding author) will receive an email asking you to login or register with Author Services. You will be asked to sign a publication license at this point.

Once your paper is typeset you will receive an email notification of the URL from where to download a PDF typeset page proof, associated forms and full instructions on how to correct and return the file.
Please note that you are responsible for all statements made in your work, including changes made during the editorial process and thus you must check your proofs carefully. Note that proofs should be returned 48 hours from receipt of first proof.

Early View
The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before your article appears online, as Editors also need to review proofs. Once your article is published on Early View no further changes to your article are possible. Your Early View article is fully citable and carries an online publication date and DOI for citations.


Access and sharing
When your article is published online:
• You receive an email alert (if requested).
• You can share a link to your published article through social media.
• • The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to your article.
Now is the time to start promoting your article. Find out how to do that here.

Measuring the Impact of your Work
Wiley also helps you measure the impact of your research through our specialist partnerships with Kudos and Altmetric.


For queries about submissions, please contact

Author Guidelines Updated 22nd May 2017